The main purpose of this research study is to find out if de-escalation of chemotherapy before surgery followed by a selective escalation of adjuvant targeted therapies are efficacious and tolerable in early-stage HER2 positive breast cancer.

Start Date11 Aug 2024

Sponsor / Collaborator

University of Rochester

NCT06348134 / Not yet recruitingPhase 2IIT

Assessing the Efficacy and Safety of Optimal Neoadjuvant to Adjuvant Anti-HER2- Based Therapy in Nigerian Women With HER2+ Breast Cancer

Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery.

Start Date01 Jul 2024

Sponsor / Collaborator

The University of Chicago

NCT06324357 / RecruitingPhase 1/2

Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination With Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination With Intravenous Trastuzumab Emtansine (T-DM1) for Treatment of Patients With Advanced HER2+ Metastatic Breast Cancer (mBC) and Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (mGEAC)

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd) or with trastuzumab emtansine (T-DM1). Another purpose is to check whether zongertinib in combination with T-DXd or with T-DM1 can make tumours shrink. Zongertinib inhibits HER2. HER2 causes cancer cells to grow.
The study is split into treatment cycles. All study participants are treated with zongertinib in combination with T-DXd or with T-DM1. This study has 2 parts. In Part 1, participants receive increasing doses of zongertinib. In Part 2, participants are put into different groups by chance. Each group receives a different dose of zongertinib. Every participant has an equal chance of being in each group.
During the study, the participants visit the study site regularly. In this study, researchers want to find the highest dose of zongertinib that participants can tolerate when taken together with T-DXd or with T-DM1. To find this out, researchers look at certain severe health problems that a number of participants have. The doctors regularly check the size of the tumour with imaging methods (CT/MRI) during the study. The doctors also regularly check participants' health and take note of any unwanted effects.

Start Date23 May 2024

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with ADO-Trastuzumab Emtansine

100 Translational Medicine associated with ADO-Trastuzumab Emtansine

100 Patents (Medical) associated with ADO-Trastuzumab Emtansine

1,206

Literatures (Medical) associated with ADO-Trastuzumab Emtansine

01 Mar 2024·Critical reviews in oncology/hematology

Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates

Review

Author: Natangelo, Stefano ; Curigliano, Giuseppe ; Trapani, Dario ; Boscolo Bielo, Luca ; Marvaso, Giulia ; Koukoutzeli, Chrysanthi ; Jereczek-Fossa, Barbara Alicja

Antibody-drug conjugates (ADCs) represent a therapeutic class of agents designed to selectively deliver cytotoxic payloads to cancer cells. With the increasingly positioning of ADCs in the clinical practice, combinations with other treatment modalities, including radiation therapy (RT), will open new opportunities but also challenges. This review evaluates ADC-RT interactions, examining therapeutic synergies and potential caveats. ADC payloads can be radiosensitizing, enhancing cytotoxicity when used in combination with RT. Antigens targeted by ADCs can have various tissue expressions, resulting in possible off-target toxicities by tissue radiosensitization. Notably, the HER-2-directed ADC trastuzumab emtansine has appeared to increase the risk of radionecrosis when used concomitantly with brain RT, as glial cells can express HER2, too. Other possible organ-specific effects are discussed, such as pulmonary and cardiac toxicities. The lack of robust clinical data on the ADC-RT combination raises concerns regarding specific side effects and the ultimate trade-off of toxicity and safety of some combined approaches. Clinical studies are needed to assess ADC-RT combination safety and efficacy.

02 Feb 2024·The oncologist

Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study

Review

Author: Liu, Xiaoran ; Li, Huiping ; Gui, Xinyu ; Yan, Ying ; Song, Guohong ; Liang, Xu ; Di, Lijun

Abstract:

Background:

Pyrotinib is currently approved for the treatment of HER2-positive advanced breast cancer in China. Data on the overall survival (OS) and efficacy in patients with brain metastasis (BM) remain scarce. This study evaluated the effectiveness of pyrotinib in a real-world setting, especially in patients with BM.

Methods:

We reviewed patients with metastatic breast cancer treated with pyrotinib-based therapy between June 2018 and June 2022. Progression-free survival (PFS), OS, objective response rate, and safety were analyzed following the administration of pyrotinib.

Results:

A total of 239 patients were included. The median PFS in patients who received pyrotinib-based therapy as first-line (15/239), second-line (115/239), or third-or-higher-line (109/239) treatment was 14.00, 9.33, and 8.20 months, respectively, and the median OS was not reached, 29.07 and 22.23 months, respectively. The median PFS in patients who pretreated with trastuzumab (214/239), trastuzumab plus pertuzumab (22/239), lapatinib (68/239), or trastuzumab emtansine (14/239) was 9.33, 6.87, 7.20, and 7.20 months, respectively. In 61 patients with BM, the median PFS was 7.50 months, the median central nervous system (CNS)-PFS was 11.17 months, and the median OS was 21.27 months. Furthermore, 19 patients with concomitant brain radiotherapy tended to achieve a longer OS than 42 patients without radiation (34.17 vs. 20.70 months, P = .112).

Conclusions:

Long-term outcomes of pyrotinib-based therapy are promising for patients with HER2-positive metastatic breast cancer in real world and in patients with BM, regardless of the treatment lines and prior anti-HER2 therapies.

01 Feb 2024·Chinese journal of integrative medicine

Clean-DM1, a Korean Polyherbal Formula, Improves High Fat Diet-Induced Diabetic Symptoms in Mice by Regulating IRS/PI3K/AKT and AMPK Expressions in Pancreas and Liver Tissues

Article

Author: Lyu, Chenzi ; Wang, Piao ; Kang, Seok Yong ; Meng, Xianglong ; Ho, Tianjun ; Lee, Kyung Jae ; Liu, Yi ; Jung, Hyo Won ; Park, Yong-Ki ; Han, Xiang

OBJECTIVE:

To investigate the effects of Clean-DM1 (C-DM1), a polyherbal formulation of Radix Scrophulariae, Radix Astragali, Rhizoma Atractylodis, and Radix Salviae Miltiorrhizae, on high-fat diet (HFD)-induced diabetes mice.

METHODS:

The information about active components of C-DM1 extract and molecular mechanism was obtained from network pharmacology analysis. Main compounds of C-DM1 extract by high performance liquid chromatography-mass spectrometry (HPLC-MS) analysis were conducted for quality control. For in vivo study, mice were induced diabetes by HFD for 12 weeks. The mice in the normal group (Nor) were maintained with a regular diet and treated with saline by gavage. The HFD model mice were randomly divided into 3 groups, including a HFD diabetic model group, a C-DM1 extract-administered group (C-DM1, 500 mg/kg), and metformin-administered groups (Met, 500 mg/kg), 8 mice in each group. Food intake, body weight (BW), and fasting blood glucose (FBG) levels were recorded weekly for 4 weeks. After 4 weeks of treatment, alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood glucose, low-density lipoprotein cholesterol (LDL-C) were determined using an automated clinical chemistry analyzer, and homeostatic model for assessing insulin resistance (HOMA-IR) levels and oral glucose tolerance test (OGTT) were detected. The histopathological changes of liver and pancreatic tissues were observed by hematoxylin-eosin staining. Insulin receptor substrate (IRS)/phosphatidylinositol 3 kinase (PI3K)/ protein kinase B (AKT) and adenosine 5'-monophosphate-activated protein kinase (AMPK) expressions in liver and pancreas tissues were detected by Western blot analysis.

RESULTS:

HPLC-MS identified dihydroisotanshinone, dihydroisotanshinone I, cryptotanshinone, harpagoside, and atractyloside A in C-DM1 extract. The administration of C-DM1 extract significantly decreased body weight, calorie intake, and the levels of blood glucose and insulin in the diabetic mice (P<0.05 or P<0.01). The C-DM1 extract administration improved the impaired glucose tolerance and insulin resistance in the diabetic mice and significantly decreased the levels of LDL-C, ALT and AST (P<0.01). The C-DM1 extract inhibited the histopathological changes of fatty liver and hyperplasia of pancreatic islets in the diabetic mice. The C-DM1 extract significantly increased the phosphorylation of IRS, AKT, and AMPK and the expression of PI3K in pancreas and liver tissues (P<0.05 or P<0.01), which was consistent with the analysis results of network pharmacology.

CONCLUSION:

C-DM1 extract improved diabetes symptoms in long-term HFD-induced mice by regulation of IRS/PI3K/AKT and AMPK expressions in pancreas and liver tissues, suggesting that C-DM1 formulation may help prevent the progression of T2DM.

111

News (Medical) associated with ADO-Trastuzumab Emtansine

01 Jul 2024

·pipelinereview.com

Zydus and Dr. Reddy’s announce licensing agreement for co‐marketing of Pertuzumab biosimilar, a critical treatment for breast cancer patients in India

Pertuzumab biosimilar developed by Zydus is a critical treatment for HER2 positive breast cancer and is being launched jointly by Zydus and Dr. Reddy’s in India The product will be marketed by Zydus under the brand name Sigrima ™ while Dr. Reddy’s will market it under the brand name Womab ® . AHMEDABAD & HYDERABAD, India I June 28, 2024 I Zydus Lifesciences Limited (including its subsidiaries/affiliates hereafter referred to as “Zydus”) a discovery-driven global lifesciences company and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), a global pharmaceutical company, announced the execution of a licensing agreement to co-market Pertuzumab biosimilar in India. Pertuzumab is a critical treatment for HER2 positive breast cancer patients. The biosimilar has been developed in-house by the research team at the Zydus Research Centre (ZRC). Under the terms of this agreement, Dr. Reddy’s will receive semi-exclusive rights from Zydus to co-market the product in India. The product will be marketed by Zydus under the brand name Sigrima™. Dr. Reddy’s will market it under the brand name Womab®. Zydus will receive upfront licensing income and is eligible to receive milestone income based on achievement of pre-defined milestones. Speaking on the development, spokesperson from Zydus Lifesciences Ltd., said, “Our basket of cancer care therapies which includes cytotoxic, supportive and targeted drugs, has had a significant impact on patient survival and the quality of life. We are committed to providing comprehensive care for HER2-positive patients and with the launch of this critical drug, we will be offering all the three essential drugs, SigrimaTM, Pertuzumab biosimilar, VivitraTM the largest selling trastuzumab biosimilar and UjviraTM the world’s first antibody drug conjugate biosimilar of trastuzumab emtansine. Together, these treatments represent a significant advancement in HER2-targeted therapy. We are pleased to join hands with Dr. Reddy’s to expand the access to this novel medicine.” Spokesperson from Dr. Reddy’s, said, “Oncology is a key therapy area for us, and we are working to offer a diverse portfolio of offerings from standard of care, innovations in formulations, access to novel medicines and beyond-the-pill initiatives. We are happy to collaborate with Zydus to make this breast cancer drug available to patients in India. HER2 positive breast cancer patients require access to a combination of Trastuzumab and Pertuzumab, along with chemotherapy. We already offer biosimilar Trastuzumab (Hervycta®). With this product, we will be able to provide the complete standard of care to HER2 positive breast cancer patients in India.” Human epidermal growth factor 2 (HER2) is a protein that makes cells grow and divide. Some cancers have large amounts of HER2 protein and are known as HER2-positive cancers. These cancers tend to spread fast if not treated optimally. There is an estimate of over 2,30,000 new cases of breast cancer in 2025 and around 25% of these can be HER2-positive. Pertuzumab is an anti-HER2 monoclonal antibody (mAB) and it works by locking onto HER2 on the cancer cells, supressing HER2-mediated cell proliferation. Pertuzumab is recommended for both early and late stage HER2-positive breast cancers in combination with other drugs such as trastuzumab and chemotherapy. Its addition helps in different ways like shrinking the cancerous tumour, making the surgery less extensive, conserving the breast tissue, delaying the cancer coming back, halting the cancer spread, increasing the lifespan etc. Every HER2 positive patient needs to have access to combination of Trastuzumab and Pertuzumab, however, less than 5% patients have access to the same.1 With the launch of Pertuzumab in India, many more patients in need can benefit from the access to combination therapy. Appendix: 1. Breast cancer incidence: https://acsjournals-onlinelibrary-wiley-com.libproxy1.nus.edu.sg/doi/10.1002/cncr.35188#:~:text=Breast%20cancer%20is%20the%20most%20common%20cancer%20in%20India%2C%20accounting,estimated%20216%2C108%20cases%20by%202022.&text=The%20age%2Dstandardized%20incidence%20rate,over%20the%20past%2026%20years Breast cancer is the most common cancer in India, accounting for 28.2% of all female cancers, with an estimated 216,108 cases by 2022 HER2 positive: https://www-nature-com.libproxy1.nus.edu.sg/articles/s41598-020-62618-3 Hormone receptor positive/HER2 negative, triple negative (TNBC) and hormone receptor any/HER2 positive cases were 55.2%, 24.2% and 20.6%, respectively. Access of Pertuzumab today: IPSOS Dec’23 Data About Zydus: Zydus Lifesciences Ltd. with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs 26,000 people worldwide, including 1,400 scientists engaged in R & D, and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. Zydus has been actively discovering and developing New Chemical Entities (NCEs) novel biologicals, several biosimilars and vaccines as a part of its innovation pipeline. Over the last decade, Zydus has introduced several innovative, first-in-class products in the market for treating unmet healthcare needs with vaccines, therapeutics, biologicals and biosimilars. The group aspires to transform lives through path-breaking discoveries. For more details visit www.zyduslife.com About Dr. Reddy’s Laboratories Ltd: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com . SOURCE: Dr. Reddy’s

License out/inDrug Approval

28 Jun 2024

·www.drugs.com

Combo Drug Boosts Survival in Some Women With Early Breast Cancer

FRIDAY, June 28, 20204 (HealthDay news) -- An immunotherapy/chemotherapy combo drug can help early-stage breast cancer patients remain cancer-free following treatment, a new trial shows. The combo drug, Kadcyla , is already approved to treat patients with advanced HER2-positive breast cancer, researchers said. The new results show that stage 1 breast cancer patients who received Kadcyla stayed free of invasive cancer five years after treatment. “One year of [Kadcyla] after surgery for patients with a stage 1 HER2-positive cancer leads to outstanding long-term outcomes, making it a reasonable treatment approach for select patients,” said senior study author Dr. Sara Tolaney , chief of breast oncology at Dana-Farber Cancer Institute in Boston. HER2-positive breast cancers are fueled by a protein that normally helps control cell growth. Cancer cells that make too much HER2 might grow more quickly and are more likely to spread to other parts of the body. Patients with early HER2-positive breast cancer have their cancers return 5% to 30% of the time following initial treatment, said lead researcher Dr. Paolo Tarantino , also with Dana-Farber. The immunotherapy drug trastuzumab helps inhibit HER2-positive cancers by blocking that protein. When given alongside chemotherapy after breast cancer surgery, trastuzumab can significantly reduce the risk cancer will recur in these patients, Tarantino said. “But the side effects can have a detrimental impact on patients' quality of life.” Tarantino added. Kadcyla is a single drug that combines trastuzumab with the chemo drug emtansine. It was developed to provide the benefits of chemotherapy and immunotherapy while limiting toxic side effects. For the new clinical trial, researchers recruited 512 patients at cancer centers across the United States, with 384 receiving Kadcyla and 128 treated with chemo alongside trastuzumab. Five years after treatment, 97% of patients who got Kadcyla had no evidence of cancer recurrence. The rate of toxic side effects were similar between the two groups, but patient-reported outcomes showed better quality of life with Kadcyla, researchers said. Patients had less nerve damage, less hair loss and better work productivity with Kadcyla than with chemo and trastuzumab given separately. The trial was funded in part by Genentech, the maker of Kadcyla. The results were published June 27 in the Journal of Clinical Oncology . Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultImmunotherapyDrug ApprovalASCO

28 Jun 2024

·www.drugs.com

Combo Drug, Kadcyla, Boosts Survival in Some Women With Early Breast Cancer

Clinical ResultImmunotherapyDrug ApprovalASCO

100 Deals associated with ADO-Trastuzumab Emtansine

External Link

KEGG	Wiki	ATC	Drug Bank
-	ADO-Trastuzumab Emtansine	L01XC14	DB05773

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	EU	Roche Registration GmbH	15 Nov 2013
Breast Cancer	IS	Roche Registration GmbH	15 Nov 2013
Breast Cancer	LI	Roche Registration GmbH	15 Nov 2013
Breast Cancer	NO	Roche Registration GmbH	15 Nov 2013
Metastatic breast cancer	EU	Roche Registration GmbH	15 Nov 2013
Metastatic breast cancer	IS	Roche Registration GmbH	15 Nov 2013
Metastatic breast cancer	LI	Roche Registration GmbH	15 Nov 2013
Metastatic breast cancer	NO	Roche Registration GmbH	15 Nov 2013
HER2 Positive Breast Cancer	US	Genentech, Inc.	22 Feb 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastroesophageal junction adenocarcinoma	Phase 3	US	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	CN	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	JP	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	AR	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	BE	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	BR	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	CA	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	CZ	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	FI	Hoffmann-La Roche, Inc.	03 Sep 2012
Gastroesophageal junction adenocarcinoma	Phase 3	FR	Hoffmann-La Roche, Inc.	03 Sep 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2024	Not Applicable	Metastatic human epidermal growth factor 2 positive carcinoma of breast HER2 2+	172	T-DM1	bgibpanlpo(kvqgxpdbjp) = gsffxbajca hucskqmbdn (efunitdtuj, 3.9 - 6.3) View more	Negative	24 May 2024
ASCO2024	Not Applicable	Adjuvant	116	Biosimilar TDM1	oxipbwitjn(blyqkrpzhd) = Common adverse effects were fatigue jjfutvcyli (nigrdfkahj ) View more	Positive	24 May 2024
NCT04589845 (TAPISTRY, AACR2024) Manual	Phase 2	HER2 Positive Solid Tumors HER2	35	Trastuzumab emtansine	yvhdowffnv(ajaemurpfm) = vrmyjdldpp oicswoqzuz (raqaszupsx, 4.8 ~ 30.3) View more	Negative	05 Apr 2024
Neoadjuvant T-DM1 and Pertuzumab (SABCS2023)	Phase 2	HER2 Positive Breast Cancer Neoadjuvant HER2 amplification	163	T-DM1 plus pertuzumab	sdgbiojkah(ipjrbnunwj) = repnvcwvbi ctixgkilsq (ijrkgdaxei, 92.9% - 99.2%) View more	Negative	05 Dec 2023
ESMO_ASIA2023	Not Applicable	Metastatic human epidermal growth factor 2 positive carcinoma of breast HER2-positive	30	T-DM1 biosimilar	murucjlzkf(kehivcllnt) = ctvftvhvod rokqhflkff (prlftdzypc, 13.46 - 17.17) View more	Positive	02 Dec 2023
ESMO2023	Not Applicable	Breast Cancer	-	Patients treated with Pertuzumab	udfxvzgrqo(dgfnxtcdhd) = bzhiweormx jvrksuxmnr (bowsqwsjdh, [60.6, 63.1])	-	21 Oct 2023
ESMO2023	Not Applicable	Breast Cancer	-	Patients treated with T-DM1 after Pertuzumab	ywjdhcggpq(jyiyroczef) = combyisdqv razruhgslc (nlsxlnckdh, [34.6 , 39.4]) View more	-	21 Oct 2023
NCT03975647 (HER2CLIMB-02, Corporate Publications) Manual	Phase 3	HER2 Positive Breast Cancer HER2 Positive	-	TUKYSA+Kadcyla	xpvpprbahh(tvmseheoyk) = met its primary endpoint of progression-free survival (PFS) uwvnhzxkuj (lsvodwcjwt ) Met	Positive	16 Aug 2023
NCT01835236 (Pubmed)	Phase 2	Metastatic human epidermal growth factor 2 positive carcinoma of breast First line	210	Pertuzumab plus Trastuzumab without chemotherapy	rbzoqeajpl(mknzqxdzsp) = rgyjhxrlbi dqqnbuijfc (dsymyrfmlw, 7.9 - 12.0) View more	-	10 Aug 2023
NCT01835236 (Pubmed)	Phase 2		210	Pertuzumab plus Trastuzumab with chemotherapy	rbzoqeajpl(mknzqxdzsp) = hewiffhwxd dqqnbuijfc (dsymyrfmlw, 18.9 - 33.1) View more	-	10 Aug 2023
NCT03529110 (DESTINY-Breast03, Pubmed)	Phase 3	Metastatic human epidermal growth factor 2 positive carcinoma of breast HER2-positive	-	Trastuzumab deruxtecan (T-DXd)	fceycqylov(futeltlxyw) = TDD analyses of QLQ-C30 GHS (primary PRO variable) and all other prespecified PROs (QLQ-C30 subscales, the QLQ-BR45 arm symptoms scale, and the EQ-5D-5L visual analogue scale) suggested T-DXd was numerically favored over T-DM1 based on TDD hazard ratios gtmxhfqsds (avawjdhcvo ) View more	Positive	01 Jul 2023
NCT03529110 (DESTINY-Breast03, Pubmed)	Phase 3		-	Trastuzumab emtansine (T-DM1)		Positive	01 Jul 2023
NCT02675829 (ASCO2023) Manual	Phase 2	Neoplasms ERBB2 Amplification	88	Ado-trastuzumab emtansine 3.6 mg/kg	wjprnznymr(fqdojyjipu) = jdtgvuwmfv hyhewxunzp (hifxysneoe, 24 - 44) View more	Positive	31 May 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis